Alpex Pharma SA
Alpex Pharma SA is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Alpex Pharma SA.
Alpex Pharma SA is a company.
Key people at Alpex Pharma SA.
Key people at Alpex Pharma SA.
Alpex Pharma SA is a Swiss research-based pharmaceutical company specializing in end-to-end drug development, formulation, clinical trials, product registration, manufacturing, and global export of innovative pharmaceutical and nutraceutical products.[1][2][3] It focuses on advanced drug delivery technologies like orally disintegrating tablets (ODT or "fast melt"), effervescent tablets, and sustained-release formulations, serving global pharmaceutical partners by addressing unmet needs in areas such as obesity, pain management, respiratory issues, and kidney disease.[1][2][4][6] With 7000 square meters of GMP-compliant facilities in Mezzovico, Ticino, the company generates around $11.3 million in annual revenue and employs about 44-67 people, scaling breakthroughs for aging populations and improved healthcare access.[1][2][4]
Founded in 1988 in Switzerland, Alpex Pharma SA began with a mission to develop medicines for untreated areas, quickly gaining traction when acquired by Irish firm Elan Pharma, which expanded its neuroscience drug development as Elan's Swiss R&D hub.[3] This period saw the creation of multiple proprietary drugs, patents, and unique delivery systems applicable to existing pharmaceuticals, building a global client base among leading pharma companies.[3] In 2020, entrepreneurs acquired the company to scale longevity-focused innovations, blending Alpex's technologies with modern active pharmaceutical ingredients (APIs).[3] Now over 35 years old, it maintains a reputation for Swiss precision, having developed dozens of drugs for demanding global markets under Managing Director Shahbaz Ardalan.[2][3]
Alpex rides the wave of next-generation pharma trends like advanced drug delivery for patient-centric dosing (e.g., no-water ODTs improving adherence) amid rising demand from aging populations, chronic diseases, and global healthcare access.[1][6] Its timing aligns with lifecycle management needs, extending patents via reformulations, and supports biopharma scaling through contract manufacturing for complex APIs.[3][6] In Switzerland's precision pharma ecosystem, Alpex influences by partnering with majors, fostering innovation in underserved areas like respiratory and renal care, and enabling faster global market entry.[1][3]
Alpex is poised to expand its innovation pipeline in longevity and targeted therapeutics, leveraging 35+ years of patents and global partnerships to capture growth in personalized medicine and nutraceuticals.[1][3] Trends like AI-driven formulation, rising obesity/pain markets, and sustainable manufacturing will shape its path, potentially boosting revenue beyond $11.3M via new API integrations and exports.[2][6] Its influence may evolve as a key enabler for big pharma's delivery challenges, solidifying Swiss leadership in scaling medicinal breakthroughs from R&D to market.[1][3]
